Lars Christian Wilde

Thank you for speaking up, Robin. One important additional point: psychedelic therapies are currently being developed largely for treatment-resistant patients who have already failed one or more SSRIs/SNRIs. Suggesting that SSRIs may therefore be more beneficial than psychedelic therapies makes little clinical sense.

Very silly headline to run based on a comparative analysis of apples vs oranges.

@fkuhlmann @insidepharma @HelusPharma no true separation from placebo

@insidepharma @HelusPharma That all sounds pretty good and not really surprising. The only question is, why on earth is the price crashing so drastically? What do i miss???

Thrilled to see fresh progress in addressing the huge unmet need in generalized anxiety disorder (GAD) @HelusPharma $HELP today released topline results from a Phase 2 signal detection study of HLP004 - an investigational intramuscular deuterated serotonergic 2A agonist designed to activate serotonin pathways and promote neuroplasticity - as an adjunctive treatment for adults with moderate-to-severe GAD who remain symptomatic despite ongoing standard-of-care antidepressants. Key takeaways from the 36-patient, 2:1 randomized trial (20 mg or 2 mg IM doses, administered twice three weeks apart): - 20 mg arm: -10.4 point mean HAM-A reduction at Week 6 vs baseline (p < 0.0001) - a clinically meaningful add-on benefit beyond ongoing SSRIs/SNRIs/etc. - Week 6 response rate (≥50% HAM-A reduction): 59%; remission (HAM-A ≤7): 32% in the 20 mg group. - Durability: Pooled data at 6 months showed 67% response and 39% remission. - Safety: Generally well-tolerated, transient AEs, no drug-related SAEs, no suicidality signals. Acute effects ~90 minutes; discharge-ready within ~3 hours. In a field where ~50% of GAD patients fail to achieve adequate response to first-line therapy - and no adjunctive pharmacologic option is approved - these results are encouraging. Current monotherapies (e.g., escitalopram, duloxetine, pregabalin) typically deliver 2–4 point placebo-adjusted HAM-A improvements in broader populations; HLP004’s added magnitude in a treatment-resistant cohort stands out. HLP004’s adjunctive profile, with a two-dose regimen and long-lasting effects, could fit real-world clinic workflows. - Addresses resistant GAD without replacing existing antidepressants. - Feasible short in-clinic experience (no overnight stays). - Sustained benefit (6+ months observed) means infrequent clinic visits. - Scalable if Phase 3 confirms - especially important given the 20M+ U.S. adults affected by GAD. Of course, this is early Phase 2 data; larger trials are needed to confirm efficacy, safety, and optimal dosing. But the signal is strong. Huge congrats to the Helus team and investigators. Looking forward to next steps - and more options for patients who need them. #MentalHealth #GAD #Biotech #Pharma #Neuroplasticity #Psychedelics

@StevePhillipsMD It does not show that. The study was unfortunately entirely uncontrolled.

New Hopkins study shows that a couple of doses of psilocybin provides benefits lasting 6 months in chronic Lyme patients. This is consistent with what I’ve seen in patients over the years. hopkinslyme.org/news/psilocybi…

For five years biotech startups have been betting that psychedelic substances could be turned into real medicines. One of them may have hit the jackpot econ.st/4rqmv1w Photo: Getty Images

Almost 10 years ago, I made the decision to bring psychedelics back into modern medicine. At the time, nearly every friend and business partner I spoke to responded with some version of: “You can’t do that.” (And that is the polite version.) But my conviction in the therapeutic potential of these compounds was strong enough to push past the skepticism and move forward. Shortly thereafter, I teamed up with George Goldsmith, Ekaterina Malievskaia, and @LarsWilde to found @COMPASSPathway. And soon after, we launched atai - now @ataibeckley (Nasdaq: $ATAI) - as the psychedelic “mothership” designed to build a portfolio of differentiated, clinically validated psychedelic medicines. AtaiBeckley still owns approx. 5% of Compass as per last filing. Today, we are close to the moment we have been working toward for almost a decade. Yesterday’s $CMPS update reconfirmed the expected timeline: a Q4 2026 NDA submission and an early 2027 commercial launch for COMP360 psilocybin. If this timeline holds, 2027 will mark the year in which psychedelic therapy becomes accessible to patients in the US within a regulated medical framework. Looking back, I am especially proud of two things we have achieved: 1. The quality and rigor of the clinical evidence generated - with more than $1bn invested by Compass and AtaiBeckley into gold standard clinical trials across multiple psychedelic compounds and indications. 2. The fundamental shift in public perception - from “counterculture” to credible, FDA-grade drug development. But the work is far from done. In my view, the next phase of this sector will be driven less by broad sentiment and more by fundamentals. Mental health is not a single disease category, and different root causes will require different therapeutic approaches. The key question is no longer whether psychedelics can show efficacy with an attractive side-effect profile - that has been clear to me from day one and at least for me was never in question - but whether individual drug candidates can fit into a scalable and reimbursable commercial model. In other words: it will come down to duration, route of administration, patient convenience, and ultimately the practicality of delivering these therapies at scale. Now that we have largely established that psychedelics do work, I believe investors will increasingly focus on those details - and that this is becoming a true stock-picker’s market. I may be biased as founder and Chairman, but imo from a fundamental perspective, the choice is clear: AtaiBeckley. Here is why:

A rigorous paper published in Nature supports the idea that the Eleusinian Mysteries may have been a psychedelic-based religion. Plato, Aeschylus, Augustus, Marcus Aurelius, and Plutarch are just a few of the historically significant figures known to have participated in these rites. Given how profoundly our modern world is shaped by the ideas of these thinkers - from philosophy to governance - one could argue that Western civilization itself has, in part, been influenced by #psychedelic wisdom. Now, imagine for a moment how much more intellectually vibrant, thoughtful, and humane our world could become (again) if we responsibly reintroduced these medicines into society. nature.com/articles/s4159…

@heynavtoor Ai. Thank you

Everyone is hyped about Claude… but barely anyone knows how to actually use it to replace real work. I collected 700+ mega prompts that turn Claude into a full-blown productivity engine. Comment "AI" and I’ll DM you everything.

Today’s chatter about @COMPASSPathway's Comp360 drug being “snubbed” for a National Priority Voucher is making a mountain out of a molehill. There is this persistent false assumption that approving psychedelics for medical use could be a political issue or decision. It is not - and it should never be. Like any other novel therapeutic, psychedelic compounds must demonstrate efficacy and safety through rigorous, FDA-regulated clinical trials. The good news: multiple late-stage programs are reaching maturity, and I believe the coming years will be a watershed moment for the field as data continue to meet the FDA’s gold-standard approval bar. As the article notes itself, the National Priority Voucher is - at least in part - a political decision. I was - and remain - extremely skeptic to make psychedelics a “political thing”. We have to acknowledge that these therapeutics come with a history and “baggage”. Not fair, but historical fact. This is why, since the founding of @ataibeckley, I have continuously pushed for us to go the extra mile. Cutting corners, or even giving people the impression of doing that, would be of huge disservice to the entire field. This is why I have been vocally critical about how Lykos handled their imo justified rejection, for example. Today’s headline is another try to make this a political story. Because the Trump administration can be a polarizing topic, it makes the narrative even more enticing for some. But already within the article itself – which is much more balanced than the headline, but behind a paywall – one can read, correctly, that the voucher in any case wouldn’t have changed anything more or less, and that “the FDA is allowing … to submit data on a rolling basis, which should get Compass a decision potentially late this year or early next year, much earlier than previously expected.” I fully agree with an analyst who is quoted that “Compass’ exclusion from the voucher program might even be a blessing in disguise… Approving the first psychedelic medication through a controversial FDA pathway could raise questions about whether corners were cut as part of an expedited review, setting back the field.” I want to say it again: #psychedelics have shown real, meaningful potential as therapeutics for mental‑health disorders. The rigorous FDA process will decide where they land, but nothing about this field requires shortcuts or political favors. The data - as they continue to emerge - will speak for themselves. $ATAI $CMPS $GHRS $DFTX

@OwenShroyer1776 @grok who is Ronald Bernard. What banks did he work for?

Never forget when Dutch Banker Ronald Bernard talked about the elites being into human sacrifice and 'child sacrifice abroad'.

Billionaire @C_Angermayer is one of the world’s most prolific entrepreneurs and investors in technology and biotech. And his psychedelic drug development company is on a mission to change the future of psychedelic medicines in America. $ATAI thenew.money/article/christ…

Great to see #atai and my co-founder @C_Angermayer take a leadership position in shaping the dialogue around mental health and the urgently needed innovation to finally halt and hopefully reverse the epidemic of psychiatric disorders and skyrocketing deaths of despair (suicide, overdose). #psychedelics #interventionalpsychiatry #mentalhealth

#MentalHealth #PsychedelicMedicine #Neuroplasticity #Biotech #Psychedelics #Spravato #5meodmt #5meo #ataibeckley

Two intranasal doses of BPL-003 (5-MeO-DMT) achieved 81% response and 67% remission in treatment-resistant depression — with effects lasting 4 months and avg. discharge < 2 h. Built for efficacy and scale. Read more ↓ brandflorian.substack.com/p/why-bpl-003-…

“Psychedelics will also get a dedicated session: a fireside chat with German billionaire investor @C_Angermayer , the founder and chair of psychedelics company @ataibeckley.” $ATAI politico.com/news/2025/11/1…

1/ 🚀 BPL-003 News: Highly encouraging new data from the open-label extension of @ataibeckley's Phase 2b study of 5-MeO-DMT (BPL-003). 👉 81 % response 👉 67 % remission in treatment-resistant depression 4 months post first dose $ATAI $CMPS $MNMD $GHRS

Most people think of #psychedelics as treatments for mental-health conditions - and rightly so. These powerful therapeutics hold extraordinary potential to help people heal from depression, anxiety, addiction, and PTSD. But I believe their potential extends far beyond mental-health care. Psychedelics may, in fact, be exactly what humanity needs to evolve from our current state of society into a post-A(G)I world. In the years ahead, I see a real risk that humanity could drift toward a kind of collective instability - even madness. The warning signs are already all around us: mental-health disorders are soaring, antidepressant use is at record levels, suicide rates continue to climb, and we face a global epidemic of loneliness and anxiety. Human cognition evolved under conditions of slow, almost static change. Our nervous systems and social structures were built for a world that remained stable for millennia. Now, artificial intelligence is reshaping our environment at a speed and scale humanity has never encountered. Historically, every major technological or societal disruption - each far smaller and slower than what AI is bringing - has unleashed profound psychological stress, often leading to conflict or collapse. The difference today is that, for the first time, we have a tool that could help us navigate such transformation: psychedelics. When properly understood and applied in medical settings, they offer a pathway to realign mind and environment - to foster resilience and coherence in an age of exponential change. Read more in my latest post about $ATAI

I have no plans to die anytime soon - quite the opposite! My mission is to reach longevity escape velocity. So relax, my fellow psychedelic enthusiasts - the adventure has only just begun 🚀🍄

@aaditsh AI

Perplexity just quietly dropped a 42-page internal guide on how they actually use AI at work. What I found most useful: → How they automate the small stuff. Email, meeting prep, research (all done by AI) → Using AI to amplify your curiosity, not replace it. → Their prompting playbook is simple, practical, and genuinely good. Comment “AI” and I’ll send it to you for free.

Great progress for psychedelic therapy rollout:

#atai 💪🏻